Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works

Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States

Wong, R. J., Aguilar, M. E. F., Cheung, R. C., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,821 · see citing works

Molecular mediators of hepatic steatosis and liver injury

Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · see citing works

Pharmacology, physiology, and mechanisms of incretin hormone action.

Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · see citing works

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

Yki‐Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,260 · see citing works

Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications

Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 917 · see citing works

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · see citing works

Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace

Baffy, G., Brunt, E. M., & Caldwell, S. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.027 · Cited by 856 · see citing works

Lipotoxicity and the gut-liver axis in NASH pathogenesis

Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847 · see citing works

Inflammatory mechanisms in the regulation of insulin resistance

Tilg, H., & Moschen, A. R. (2008) · Molecular Medicine · doi:10.2119/2007-00119.tilg · Cited by 779 · see citing works

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · see citing works

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641 · see citing works

Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis

Mantovani, A., Byrne, C. D., Bonora, E., & Targher, G. (2018) · Diabetes Care · doi:10.2337/dc17-1902 · Cited by 634 · see citing works

Recent insights into the pathogenesis of nonalcoholic fatty liver disease

Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573 · see citing works

Glucagon-like peptide 1 in health and disease

Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · see citing works

Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway

Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · see citing works

The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis

Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 531 · see citing works

Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World

Sayiner, M., Koenig, A., Henry, L., & Younossi, Z. M. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.001 · Cited by 529 · see citing works

Determinants of Fibrosis Progression and Regression in NASH

Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479 · see citing works

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456 · see citing works

Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects

Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435 · see citing works

The New Biology and Pharmacology of Glucagon

Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · see citing works

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

Rotman, Y., & Sanyal, A. J. (2016) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 410 · see citing works

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405 · see citing works

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus

Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397 · see citing works

Reduced Incretin Effect in Type 2 Diabetes

Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349 · see citing works

Peripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in Rats

Dakin, C. L., Small, C. J., Batterham, R. L., Neary, N. M., Cohen, M. A., Patterson, M., Ghatei, M. A., & Bloom, S. R. (2004) · Endocrinology · doi:10.1210/en.2003-1338 · Cited by 342 · see citing works

A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease

Chen, Z., Yu, R., Xiong, Y., Du, F.-T., & Zhu, S. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0572-9 · Cited by 319 · see citing works

Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · see citing works

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279 · see citing works

Islet α cells and glucagon--critical regulators of energy homeostasis

Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266 · see citing works

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program

Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250 · see citing works

Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions

Adolph, T. E., Grander, C., Grabherr, F., & Tilg, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081649 · Cited by 243 · see citing works

Robust anti‐obesity and metabolic effects of a dual <scp>GLP</scp> ‐1/glucagon receptor peptide agonist in rodents and non‐human primates

Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240 · see citing works

Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study

Petit, J., Cercueil, J., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 228 · see citing works

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies

Blonde, L., & Russell-Jones, D. L. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01075.x · Cited by 227 · see citing works

Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226 · see citing works

Liver and diabetes. A vicious circle

Loria, P., Lonardo, A., & Anania, F. A. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01031.x · Cited by 206 · see citing works

Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease

Finan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.014 · Cited by 191 · see citing works

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

Shao, N., Kuang, H. Y., Hao, M., Gao, X. Y., Lin, W. J., & Zou, W. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2561 · Cited by 185 · see citing works

Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in <scp>J</scp>apanese patients (<scp>LEAN</scp>‐<scp>J</scp>)

Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182 · see citing works

GLP-1/glucagon receptor co-agonism for treatment of obesity

Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175 · see citing works

Should we undertake surveillance for HCC in patients with NAFLD?

Younes, R., & Bugianesi, E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.006 · Cited by 174 · see citing works

Treatment with <scp>LY</scp> 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Guzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12958 · Cited by 172 · see citing works

Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease

Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12555 · Cited by 165 · see citing works

The Mechanism of Satiety: Effect of Glucagon on Gastric Hunger Contractions in Man.

Stunkard, A. J., Itallie, T. B. V., & Reis, B. B. (1955) · Experimental Biology and Medicine · doi:10.3181/00379727-89-21776 · Cited by 160 · see citing works

Non-alcoholic Fatty Liver Disease: A Clinical Update

Pappachan, J. M., Babu, S. V., Krishnan, B., & Ravindran, N. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00013 · Cited by 157 · see citing works

Fitness Versus Fatness: Moving Beyond Weight Loss in Nonalcoholic Fatty Liver Disease

Johnson, N. A., & George, J. (2010) · Hepatology · doi:10.1002/hep.23711 · Cited by 145 · see citing works

Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome

Wainwright, P., & Byrne, C. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030367 · Cited by 145 · see citing works

Direct effect of GLP-1 infusion on endogenous glucose production in humans

Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E. (2013) · Diabetologia · doi:10.1007/s00125-012-2738-3 · Cited by 143 · see citing works

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142 · see citing works

Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission

Wild, S. H., Walker, J. J., Morling, J. R., McAllister, D., Colhoun, H. M., Farran, B., McGurnaghan, S. J., McCrimmon, R. J., Read, S. H., Sattar, N. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1590 · Cited by 138 · see citing works

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial

Tang, A., RABASA-LHORET, R. P. R., Castel, H., Wartelle‐Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A., de Guise, J. A., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 133 · see citing works

Incretin mimetics as a novel therapeutic option for hepatic steatosis

Tushuizen, M. E., Bunck, M. C. M., Pouwels, P. J. W., van Waesberghe, J. H. T., Diamant, M., & Heine, R. J. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01315.x · Cited by 128 · see citing works

Depression of Food Intake Induced in Healthy Subjects by Glucagon

Penick, S. B., Hinkle, L. E., & Paulsen, E. G. (1961) · New England Journal of Medicine · doi:10.1056/nejm196105042641801 · Cited by 125 · see citing works

Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes

Ali, S., & Drucker, D. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90887.2008 · Cited by 124 · see citing works

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia &amp; Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122 · see citing works

Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker

Firneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012226 · Cited by 121 · see citing works

Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease

Bernsmeier, C., Meyer‐Gerspach, A. C., Blaser, L. S., Jeker, L., Steinert, R. E., Heim, M. H., & Beglinger, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087488 · Cited by 110 · see citing works

Gut hormone polyagonists for the treatment of type 2 diabetes

Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 108 · see citing works

Monomeric GLP-1/GIP/Glucagon Triagonism Corrects Obesity, Hepatosteatosis, and Dyslipidemia in Female Mice

Jall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107 · see citing works

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series

Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.363 · Cited by 106 · see citing works

The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome

Aguilar-Olivos, N. E., Almeda-Valdes, P., Aguilar-Salinas, C. A., Uribe, M., & Méndez-Sánchez, N. (2016) · Metabolism · doi:10.1016/j.metabol.2015.09.004 · Cited by 100 · see citing works

A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice

Valdecantos, M. P., Pardo, V., Ruiz, L., Castro‐Sánchez, L., Lanzón, B., Fernández‐Millán, E., García‐Monzón, C., Arroba, A. I., González‐Rodríguez, Á., Escrivá, F., et al. (2017) · Hepatology · doi:10.1002/hep.28962 · Cited by 100 · see citing works

Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial

Khoo, J., Hsiang, J., Taneja, R., Law, N., & Ang, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13007 · Cited by 99 · see citing works

Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96 · see citing works

Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma

Massoud, O. I., & Charlton, M. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.014 · Cited by 84 · see citing works

Type 2 diabetes and risk of hospital admission or death for chronic liver diseases

Wild, S. H., Morling, J. R., McAllister, D., Kerssens, J., Fischbacher, C., Parkes, J., Roderick, P. J., Sattar, N. A., & Byrne, C. D. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.014 · Cited by 83 · see citing works

Postprandial Lipemia Associates with Liver Fat Content

Matikainen, N., Mänttäri, S., Westerbacka, J., Vehkavaara, S., Lundbom, N. M. I., Yki‐Järvinen, H., & Taskinen, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0187 · Cited by 76 · see citing works

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Younossi, Z. M. (2017) · Liver Transplantation · doi:10.1002/lt.25003 · Cited by 72 · see citing works

Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism

Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60 · see citing works

Effects of lixisenatide on elevated liver transaminases: Systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005325 · Cited by 59 · see citing works

Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes

Simeone, J. C., Bae, J. P., Hoogwerf, B. J., Li, Q., Haupt, A., Ali, A. K., Boardman, M. K., & Nordstrom, B. L. (2017) · Clinical Epidemiology · doi:10.2147/clep.s144368 · Cited by 53 · see citing works

Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet

Schwenger, K. J. P., Fischer, S. E., Jackson, T. D., Okrainec, A., & Allard, J. P. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2980-3 · Cited by 51 · see citing works

Evidence of Hepatic Glucagon Resistance Associated with Hepatic Steatosis: Reversal Effect of Training

Charbonneau, A., Couturier, K., Gauthier, M., & Lavoie, J.-M. (2005) · International Journal of Sports Medicine · doi:10.1055/s-2004-821225 · Cited by 40 · see citing works

A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects

Zhou, J., Cai, X., Huang, X., Dai, Y., Sun, L., Zhang, B., Yang, B., Lin, H., Huang, W., & Qian, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.046 · Cited by 38 · see citing works

Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia

Suppli, M. P., Lund, A., Bagger, J. I., Vilsbøll, T., & Knop, F. K. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2015.10.029 · Cited by 35 · see citing works

Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk

Bozzetto, L., Annuzzi, G., Ragucci, M., Donato, O. D., Pepa, G. D., Corte, G. D., Griffo, E., Anniballi, G., Giacco, A., Mancini, M., et al. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.01.011 · Cited by 34 · see citing works

Glucagon receptor signaling in metabolic diseases

Albrechtsen, N. J. W. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.016 · Cited by 27 · see citing works

Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients

Blaslov, K., Zibar, K., Bulum, T., & Duvnjak, L. S. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2013.10.013 · Cited by 14 · see citing works

The role of incretin hormones and glucagon in patients with liver disease.

Junker, A. E. (2017) · PubMed · Cited by 10 · see citing works

Blockade of glucagon-like peptide-1 receptors by exendin(9-39) attenuates the increase in heart rate during small intestinal glucose infusion in type 2 diabetes

Rayner, C. K., Wu, T., Horowitz, M., & Jones, K. L. (2017) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.1007/s00125-017-4350-z · Cited by 1 · see citing works

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528 · see citing works

NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2

Marušić, M., Paić, M., Knobloch, M., & Pršo, A.-M. L. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/6613827 · Cited by 240 · see citing works

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

Flint, A., Andersen, G., Hockings, P., Johansson, L., Morsing, A., Sundby Palle, M., Vogl, T., Loomba, R., & Plum‐Mörschel, L. (2021) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/apt.16608 · Cited by 224 · see citing works

A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220 · see citing works

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview

Marchisello, S., Pino, A. D., Scicali, R., Urbano, F., Piro, S., Purrello, F., & Rabuazzo, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081948 · Cited by 194 · see citing works

Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease

Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179 · see citing works

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

Bossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179 · see citing works

Inter‐organ communication: a gatekeeper for metabolic health

Castillo‐Armengol, J., Fajas, L., & Lopez‐Mejia, I. C. (2019) · The EMBO Reports · doi:10.15252/embr.201947903 · Cited by 178 · see citing works

Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease

Saran, A., Dave, S., & Zarrinpar, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.050 · Cited by 172 · see citing works

Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD

Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1696 · Cited by 153 · see citing works

The intestine as an endocrine organ and the role of gut hormones in metabolic regulation

Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144 · see citing works

Metabolic Targets in Nonalcoholic Fatty Liver Disease

Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 142 · see citing works

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03302-1 · Cited by 110 · see citing works

GLP-1a: Going beyond Traditional Use

Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102 · see citing works

Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial

Khoo, J., Hsiang, J., Taneja, R., Law, N., & Ang, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13007 · Cited by 99 · see citing works

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence

Muzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 99 · see citing works

Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide

Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70 · see citing works

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides

Kořínková, L., Pražienková, V., Černá, L., Karnošová, A., Železná, B., Kuneš, J., & Maletı́nská, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597583 · Cited by 68 · see citing works

Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH

Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66 · see citing works

Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling

Khalil, R. M., Shata, A., El-Kader, E. M. A., Sharaf, H., Abdo, W. S., Amin, N. A., & Saber, S. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115246 · Cited by 67 · see citing works

Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis

Bandyopadhyay, S. K., Das, S., Samajdar, S. S., & Joshi, S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102849 · Cited by 73 · see citing works

Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway

Han, X., Ding, C., Zhang, G., Pan, R., Liu, Y., Huang, N., Hou, N., Han, F., Xu, W., & Sun, X. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.032 · Cited by 63 · see citing works

Glucagon's Metabolic Action in Health and Disease

Zeigerer, A., Sekar, R., Kleinert, M., Nason, S. R., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200013 · Cited by 76 · see citing works

Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease

Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48 · see citing works

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment

Zhu, B., Chan, S., Li, J., Li, K. S., Wu, H., Cui, K., & Chen, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.742382 · Cited by 46 · see citing works

Incretin-based investigational therapies for the treatment of MASLD/MASH

Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40 · see citing works

Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 39 · see citing works

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis

Dai, Y., He, H., Li, S., Yang, L., Wang, X., Liu, Z., & An, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.622589 · Cited by 38 · see citing works

Incretin combination therapy for the treatment of non-alcoholic steatohepatitis

Kannt, A., Madsen, A. N., Kammermeier, C., Elvert, R., Klöckener, T., Bossart, M., Haack, T., Evers, A., Lorenz, K., Hennerici, W., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14035 · Cited by 37 · see citing works

SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity

Ueno, H., Ito, R., Abe, S., Ookawara, M., Miyashita, H., Ogino, H., Miyamoto, Y., Yoshihara, T., Kobayashi, A., Tsujihata, Y., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255885 · Cited by 37 · see citing works

The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror

Martínez, M. S., Manzano, A., Olivar, L. C., Nava, M., Salazar, J. J., D’Marco, L., Ortíz, R., Chacín, M., Guerrero‐Wyss, M., de Bravo, M. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179504 · Cited by 37 · see citing works

Thioredoxin/Glutaredoxin Systems and Gut Microbiota in NAFLD: Interplay, Mechanism, and Therapeutical Potential

Zhu, M., Dagah, O. M. A., Silaa, B. B., & Lu, J. (2023) · Antioxidants · doi:10.3390/antiox12091680 · Cited by 38 · see citing works

Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression

Chen, X., Xu, Y., Wu, R., Chen, Z., Fang, K., Han, Y.-X., Yu, Y., Huang, L.-L., Peng, L., & Ge, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00434 · Cited by 35 · see citing works

Renin–Angiotensin System in Liver Metabolism: Gender Differences and Role of Incretins

Mastoor, Z., Diz-Chaves, Y., González-Matías, L. C., & Mallo, F. (2022) · Metabolites · doi:10.3390/metabo12050411 · Cited by 32 · see citing works

The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight

Ookawara, M., Matsuda, K., Watanabe, M., & Moritoh, Y. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000046 · Cited by 29 · see citing works

Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway

Ao, N., Ma, Z., Yang, J., Jin, S., Zhang, K., Luo, E., & Du, J. (2020) · Peptides · doi:10.1016/j.peptides.2020.170375 · Cited by 29 · see citing works

Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis

Góralska, J., Raźny, U., Polus, A., Dziewońska, A., Gruca, A., Zdzienicka, A., Dembinska-Kiec, A., Solnica, B., Micek, A., Kapusta, M., et al. (2020) · Nutrients · doi:10.3390/nu12020476 · Cited by 25 · see citing works

Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)

Ali, M., Parveen, S., Williams, V. R., Dons, R. F., & Uwaifo, G. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100341 · Cited by 32 · see citing works

Fatty kidney: A possible future for chronic kidney disease research

Kanbay, M., Çöpür, S., Demiray, A., Sag, A. A., Covic, A. C., Ortíz, A., & Tuttle, K. R. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13748 · Cited by 24 · see citing works

The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease

Munteanu, C., & Schwartz, B. (2023) · Antioxidants · doi:10.3390/antiox12040903 · Cited by 24 · see citing works

A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?

Vincent, R. K., Williams, D. M., & Evans, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14196 · Cited by 21 · see citing works

Anti-inflammatory effects of GLP-1 in patients with COVID-19

Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1964955 · Cited by 21 · see citing works

Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status

Bea, S., Jeong, H. E., Filion, K. B., Yu, O. H., Cho, Y. M., Lee, B. H., Chang, Y., Byrne, C. D., & Shin, J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.49856 · Cited by 21 · see citing works

Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome

Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 21 · see citing works

Preventing Oxidative Stress in the Liver: An Opportunity for GLP-1 and/or PASK

Hurtado-Carneiro, V., Dongil, P., Pérez-García, A., Álvarez, E., & Sanz, C. (2021) · Antioxidants · doi:10.3390/antiox10122028 · Cited by 18 · see citing works

Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity

Zhihong, Y., Chen, W., Qianqian, Z., Lidan, S., Zhou, Q., Han, J. D. J., Wenxi, W., & Bhawal, R. P. (2023) · Peptides · doi:10.1016/j.peptides.2023.170955 · Cited by 17 · see citing works

Glucagon's Metabolic Action in Health and Disease

Zeigerer, A., Sekar, R., Kleinert, M., Nason, S. R., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive physiology · doi:10.1002/j.2040-4603.2021.tb00161.x · Cited by 18 · see citing works

GPCRs get fatty: the role of G protein-coupled receptor signaling in the development and progression of nonalcoholic fatty liver disease

Kurtz, R., Anderman, M. F., & Shepard, B. D. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00275.2020 · Cited by 16 · see citing works

Gut-Derived Peptide Hormone Analogues and Potential Treatment of Bone Disorders in Obesity and Diabetes Mellitus

Ali, A., Flatt, P. R., & Irwin, N. (2024) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514241238059 · Cited by 12 · see citing works

From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists

Dave, B. P., Chorawala, M. R., Shah, I., Shah, N. N., Bhagat, S. U., Prajapati, B. G., & Thakkar, P. C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09793-y · Cited by 12 · see citing works

The Diabetes Syndrome – A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms

Rachfal, A. W., Grant, S. F. A., & Schwartz, S. S. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s305156 · Cited by 12 · see citing works

Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4

Errafii‬, K., Al-Akl, N. S., Khalifa, O., & Arredouani, A. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02885-4 · Cited by 12 · see citing works

Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery

Selby, L. V., Ejaz, A. M., Brethauer, S. A., & Pawlik, T. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1721457 · Cited by 12 · see citing works

Hunger & satiety signals: another key mechanism involved in the NAFLD pathway

López-Méndez, I., Maldonado-Rojas, A. D. C., Uribe, M., & Juárez-Hernández, E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1213372 · Cited by 8 · see citing works

Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives

Cazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 9 · see citing works

Ferulic acid reduces GLP‐1 degradation to ameliorate diet‐induced obesity‐associated hepatic steatosis

An, Y., Zhang, L., Fan, X., Cui, K., He, S., Ji, P., Tian, J., & Li, Z. (2024) · Food Frontiers · doi:10.1002/fft2.329 · Cited by 8 · see citing works

Metabolic Dysfunction–Associated Steatotic Liver Disease and Metabolic Dysfunction–Associated Steatohepatitis–Related Fibrosis: Therapeutic Options and Approaches to Treatment

Tincopa, M. A., Speliotes, E. K., Valenti, L. V. C., & Loomba, R. S. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050324-124753 · Cited by 7 · see citing works

Targeted MicroRNA Profiling Reveals That Exendin-4 Modulates the Expression of Several MicroRNAs to Reduce Steatosis in HepG2 Cells

Khalifa, O., Ouararhni, K., Errafii‬, K., Alajez, N. M., & Arredouani, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411606 · Cited by 7 · see citing works

A double‐blind, placebo‐controlled, single‐ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136 , a novel long‐acting glucagon analogue, in healthy subjects

Huh, K. Y., Hwang, J. G., Shin, W., Baek, S. J., Choi, J., Lee, N., Cho, Y. M., & Lee, H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14590 · Cited by 7 · see citing works

Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation

Maiwall, R., & Gupta, M. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.10.11 · Cited by 7 · see citing works

Lipid regulation of the glucagon receptor family

Oqua, A. I., Manchanda, Y., McGlone, E. R., Jones, B. J., Rouse, S. L., & Tomás, A. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0335 · Cited by 6 · see citing works

Incretin Hormones in the Control of Immunometabolism

Fishman, S., Zvibel, I., & Varol, C. (2019) · Immunometabolism · doi:10.20900/immunometab20190004 · Cited by 6 · see citing works

Hepatic Mechanisms of Myocardial Infarction: A New Perspective in Metabolic Dysfunction‐Associated Fatty Liver Disease

Cui, J., Wang, W., Xu, Q., Zhu, M., Li, Y., Liu, Y., & Liu, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040775 · Cited by 5 · see citing works

Dislipidemias, hígado graso y enfermedad cardiovascular

Hidalgo, I., Fonseca-Coronado, S., Ceballos, G. M., Meaney, E., & Nájera, N. (2022) · Cardiovascular and Metabolic Science · doi:10.35366/107628 · Cited by 5 · see citing works

Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis

Buyl, K., Vrints, M., Fernando, R. N., Desmae, T., Eeckhoutte, T. V., Jans, M., van der Schueren, J., Boeckmans, J., Rodrigues, R. M., Boe, V. D., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175989 · Cited by 5 · see citing works

Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives

Yadav, M. C., Verma, S., Tiwari, P., & Mugale, M. N. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122934 · Cited by 4 · see citing works

Traitements pharmacologiques de la NASH

Serfaty, L. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.09.015 · Cited by 4 · see citing works

Antiobesity therapeutics with complementary dual‐agonist activities at glucagon and glucagon‐like peptide 1 receptors

Park, B. G., Kim, G. M., Lee, H., Ryu, J. H., Kim, D., Seong, J. Y., Kim, S., Park, Z., Kim, Y., Lee, J., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14546 · Cited by 4 · see citing works

Obesity and Cancer: From Systemic Metabolic Reprogramming to Immunotherapy Paradox

Han, G., Yuan, S., & YU, W. (2026) · Metabolites · doi:10.3390/metabo16030174 · Cited by 3 · see citing works

Insulin resistance and type 2 diabetes as allostatic responses to chronic nutrient excess

Prentki, M., Nolan, C. J., James, D. E., Thorens, B., Rhodes, C. J., Corkey, B. E., Ling, C., Froguel, P., Mathieu, C., Gautier, J., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.06.012 · Cited by 4 · see citing works

Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management

Wibawa, I. D. N., Mariadi, I. K., Somayana, G., Kumbara, C. I. Y. K., & Sindhughosa, D. A. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.549 · Cited by 3 · see citing works

Effects of pH and Salts on the Aggregation State of Semaglutide and Membrane Filtration Performance

Duan, L., Yang, Y., Wu, H., Ding, X., & Jiang, M. (2025) · Separations · doi:10.3390/separations13010015 · Cited by 2 · see citing works

Incretin Mimetics in Cancer and Cardiovascular Disease

Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3 · see citing works

Obesity and non-alcoholic fatty liver disease: therapeutic options

Kaschenko, V., Mitsinskaya, A. I., Sokolov, A. Y., Шишкин, А. Н., Varzin, S. A., Neymark, A. E., Насрединович, М. С., Lodygin, A. V., Mitsinskiy, M., & Akhmetov, A. D. (2020) · Siberian medical review · doi:10.20333/2500136-2020-3-20-29 · Cited by 2 · see citing works

Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD

Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2025) · Diabetes mellitus · doi:10.14341/dm13340 · Cited by 1 · see citing works

Current and Future Implications of Weight Loss Drugs on Liver Disease

Bussetty, A., Shah, N., Chandler, T. M., Ghattu, M., & Kesavarapu, K. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.005 · Cited by 1 · see citing works

Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials

Zou, M., & Liu, C. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02179-z · Cited by 1 · see citing works

Serotonin receptor HTR4 as a counter actor of lipid-induced increases of serum glucagon-like peptide-1 levels

Breit, A., & Gudermann, T. W. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02454-6 · Cited by 1 · see citing works

Kardiovaskuläre Effekte von GLP-1-Rezeptoragonisten

Kahles, F., & Lehrke, M. (2020) · Diabetes aktuell · doi:10.1055/a-1152-2125

The pathophysiology of gut–liver connection

Maroni, L., Fianchi, F., Miele, L., & Svegliati‐Baroni, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821927-0.00002-4

Glucagon‐Like Peptide‐1 Receptor Activators

Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc268

Metabolic Syndrome and Liver Cancer

Jaffe, A., & Strazzabosco, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-37482-2_51-1

Advances in Biological and Clinical Research of GLP-1 Receptor Agonists

李, 鑫. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124430

Metabolic Syndrome and Liver Cancer

Jaffe, A., & Strazzabosco, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-41683-6_51

GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease

Deska, K., Bąk, B., Kosmalski, M., & Pietras, T. (2023) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2023-0001

ASSESSING THE ACCURACY OF FIB-4 SCORES TO POINT SHEAR WAVE ELASTOGRAPHY IN MONITORING DIFFERENT STAGES OF FIBROSIS IN NON-ALCOHOLIC LIVER DISEASE

Rasul, S. M. S. (2023) · Journal of Sulaimani Medical College · doi:10.17656/jsmc.10420

Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?

Sudoł, M., Dąbek, K., Ochwat, M., Piekarska, M., Skowronek, A., Kajtel, A., Mierzwa, G., & Sudoł, Z. (2024) · Quality in Sport · doi:10.12775/qs.2024.35.56304

The developmental trajectory of GLP-1 receptor agonists

Kou, B., & Qian, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00001-2

Cardio-Kidney-Metabolic Syndrome and Role of Oral Semaglutide

Roy, N., Nallaperumal, S., Mondal, S., Mathur, R., Prakash, A. S., Chakraborty, S., Vedire, A., Ankathi, S. K., Bande, A. R., & Boppana, R. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_24_26

Semaglutide and Tirzepatide Suppress Hepatic Fatty Acid Uptake and Fatty Acid β-Oxidation in High-Fat Diet-Induced Obesity Mice

Patel, D., Ewida, H. A., Tareq, S., Aziz, M. T., Chelikani, P. K., Bickel, U., & Ahmed, M. S. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00404

Duale und triagonistische Inkretine

Kirchhoff, M., & Schattenberg, J. M. (2026) · Die Gastroenterologie · doi:10.1007/s11377-026-01015-0

GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives

Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286 · see citing works

GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD

Jiang, H., & Zang, L. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128283153231226103218 · Cited by 6 · see citing works

Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)

Oshaghi, E. A. (2017) · Avicenna Journal of Medical Biochemistry · doi:10.15171/ajmb.2017.10 · Cited by 3 · see citing works

GLP-1 receptor agonists in NAFLD

Petit, J.-M., & Vergès, B. L. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30070-8 · Cited by 71 · see citing works

Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update

Sofogianni, A., Filippidis, A., Chrysavgis, L., Tziomalos, K., & Cholongitas, E. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.493 · Cited by 33 · see citing works